Celularity Appoints Richard J. Berman to its Board of Directors
Celularity Inc. (Nasdaq: CELU) has appointed Richard J. Berman to its Board of Directors. Berman brings over 40 years of experience in venture capital, senior management, and mergers and acquisitions. He has served as a director and/or officer of more than a dozen public and private companies, with six reaching over $1 billion in market value. Berman's background includes working at Goldman Sachs and as Senior Vice President at Bankers Trust Company, where he established the M&A Leveraged Buyout Departments. He has advised on over $4 billion in M&A transactions, completing over 300 deals. Celularity's CEO, Robert J. Hariri, welcomed Berman's unique depth of experience in guiding public companies and executing growth plans.
Celularity Inc. (Nasdaq: CELU) ha nominato Richard J. Berman nel suo Consiglio di Amministrazione. Berman porta con sé oltre 40 anni di esperienza nel capitale di rischio, nella gestione senior e nelle fusioni e acquisizioni. Ha ricoperto ruoli come direttore e/o dirigente in più di una dozzina di aziende pubbliche e private, con sei di esse che hanno superato il valore di mercato di 1 miliardo di dollari. Il background di Berman include esperienze presso Goldman Sachs e come Vice Presidente Senior presso Bankers Trust Company, dove ha istituito i dipartimenti di fusione e acquisizione e buyout con leva. Ha consigliato su oltre 4 miliardi di dollari in transazioni di M&A, completando più di 300 operazioni. Il CEO di Celularity, Robert J. Hariri, ha accolto la straordinaria esperienza di Berman nella guida delle aziende pubbliche e nell'esecuzione dei piani di crescita.
Celularity Inc. (Nasdaq: CELU) ha nombrado a Richard J. Berman en su Junta Directiva. Berman aporta más de 40 años de experiencia en capital de riesgo, alta dirección y fusiones y adquisiciones. Ha sido director y/o funcionario de más de una docena de empresas públicas y privadas, de las cuales seis han superado los 1.000 millones de dólares en valor de mercado. La trayectoria de Berman incluye su trabajo en Goldman Sachs y como vicepresidente senior en Bankers Trust Company, donde estableció los departamentos de M&A y compras apalancadas. Ha asesorado en transacciones de fusiones y adquisiciones por más de 4.000 millones de dólares, completando más de 300 acuerdos. El CEO de Celularity, Robert J. Hariri, dio la bienvenida a la valiosa experiencia de Berman en la orientación de empresas públicas y en la ejecución de planes de crecimiento.
셀룰라리티 Inc. (Nasdaq: CELU)는 리차드 J. 버맨을 이사회에 임명했습니다. 버맨은 벤처 캐피탈, 고위 경영 및 인수합병 분야에서 40년 이상의 경험을 가지고 있습니다. 그는 10개 이상의 상장 및 비상장 기업의 이사 및/또는 임원으로 활동했으며, 그 중 6개 기업은 시장 가치가 10억 달러를 초과합니다. 버맨의 경력에는 골드만 삭스에서의 근무와 뱅커스 신탁 회사에서 수석 부사장으로 근무한 경험이 포함되어 있으며, 여기서 그는 인수합병 레버리지 인수 부서를 설립했습니다. 그는 40억 달러 이상의 인수합병 거래를 자문하며 300건 이상의 거래를 완료했습니다. 셀룰라리티의 CEO인 로버트 J. 하리리는 공기업을 안내하고 성장 계획을 실행하는 데 있어 버맨의 독특한 경험을 환영했습니다.
Celularity Inc. (Nasdaq: CELU) a nommé Richard J. Berman à son Conseil d'Administration. Berman possède plus de 40 ans d'expérience dans le capital-risque, la haute direction et les fusions-acquisitions. Il a été directeur et/ou dirigeant de plus d'une douzaine d'entreprises publiques et privées, dont six ont atteint une valeur de marché de plus d'un milliard de dollars. Le parcours de Berman comprend une expérience chez Goldman Sachs et en tant que Vice-Président Senior chez Bankers Trust Company, où il a établi les départements d'achats à effet de levier liés aux M&A. Il a conseillé sur plus de 4 milliards de dollars en transactions de M&A, complétant plus de 300 accords. Le PDG de Celularity, Robert J. Hariri, a salué la riche expérience de Berman dans l'accompagnement des entreprises publiques et l'exécution des plans de croissance.
Celularity Inc. (Nasdaq: CELU) hat Richard J. Berman in seinen Vorstand berufen. Berman bringt über 40 Jahre Erfahrung im Bereich Risikokapital, obere Unternehmensführung sowie Fusionen und Übernahmen mit. Er hat als Direktor und/oder Geschäftsführer in mehr als einem Dutzend öffentlicher und privater Unternehmen gedient, wobei sechs von ihnen eine Marktwert von über 1 Milliarde Dollar erreicht haben. Bermans Hintergrund umfasst seine Tätigkeit bei Goldman Sachs und als Senior Vice President bei der Bankers Trust Company, wo er die Abteilungen für M&A und Leveraged Buyouts gegründet hat. Er hat bei mehr als 4 Milliarden Dollar an M&A-Transaktionen beraten und über 300 Deals abgeschlossen. Der CEO von Celularity, Robert J. Hariri, begrüßte Bermans einzigartige Erfahrung in der Führung öffentlicher Unternehmen und der Umsetzung von Wachstumsplänen.
- Appointment of experienced director Richard J. Berman to the Board
- Berman's track record of success in facilitating shareholder value growth
- Berman's extensive experience in M&A, potentially beneficial for future company growth
- None.
Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Goldman Sachs and was Senior Vice President of Bankers Trust Company where he started the M&A Leveraged Buyout Departments. He also has advised on over
"I am pleased to welcome Richard Berman to the Celularity Board of Directors, to which he brings a unique depth of experience and leadership guiding public companies and helping them build and execute growth plans,” said Robert J. Hariri, M.D., Ph.D., founder, Chairman and Chief Executive Officer of Celularity. Mr. Berman commented on his new role, “I am pleased to join Celularity at this key moment and look forward to working with Dr. Hariri and his team as it executes the Company’s focused and disciplined growth plan.”
About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet unique biology and ready availability, it can develop therapeutic solutions that address needs for effective, accessible, and affordable therapies.
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
Media Contact:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com
FAQ
Who is the new Board member appointed by Celularity (CELU)?
What experience does Richard J. Berman bring to Celularity's (CELU) Board?
How many M&A transactions has Richard J. Berman advised on?
What is Celularity's (CELU) business focus?
